Norway bails out biotech

The Norwegian government hopes to stop its country's biotech from going out of business with a $418 million boost. The money is included in a new stimulus package released by the government Monday (Jan 26). "This is the most active political move in Europe regarding support to the biotech industry," Bjarte Reve, chief executive of the Oslo Cancer Cluster, which represents 25 Norwegian biotech groups told linkurl:Financial Times.;http://www.ft.com/cms/s/0/522b1038-ebb5-11dd-8838-0000779fd2ac.htm

Written byAndrea Gawrylewski
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
The Norwegian government hopes to stop its country's biotech from going out of business with a $418 million boost. The money is included in a new stimulus package released by the government Monday (Jan 26). "This is the most active political move in Europe regarding support to the biotech industry," Bjarte Reve, chief executive of the Oslo Cancer Cluster, which represents 25 Norwegian biotech groups told linkurl:Financial Times.;http://www.ft.com/cms/s/0/522b1038-ebb5-11dd-8838-0000779fd2ac.html?nclick_check=1 Many European biotechs have been in financial freefall since last year's abysmal economic climate set in: Iceland's stock exchange was shut down in September, with prominent genetics company deCODE losing its listing on the NASDAQ biotechnology trading index, and UK biotechs clamored for a government bailout last month totaling nearly $1 billion. To put the stimulus in action, a state developmental agency called Innovation Norway is upping its loan amounts to biotech companies by $63 million a year, and a Norwegian government investment fund will also get $279 million to invest in companies focused on research.
**__Related stories:__***linkurl:Bailout for British biotech?;http://www.the-scientist.com/blog/display/55263/
[5th December 2008]*linkurl:Trouble for deCODE;http://www.the-scientist.com/blog/display/55089/
[14th October 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies